Document is current
Any future updates will be listed below
-
Authors
Schreiberhuber, Lena
Barrett, James E.
Wang, Jiangrong
Redl, Elisa https://orcid.org/0000-0001-6540-8443
Herzog, Chiara https://orcid.org/0000-0002-1572-498X
Vavourakis, Charlotte D. https://orcid.org/0000-0002-5027-2309
Sundström, Karin https://orcid.org/0000-0002-6865-0224
Dillner, Joakim https://orcid.org/0000-0001-8588-6506
Widschwendter, Martin https://orcid.org/0000-0002-7778-8380
-
Funding
Funding for this research was provided by:
EC | Horizon 2020 Framework Programme (874662, 874662)
The Land Tirol
- License Information
-
More Information
Article History
Received: 19 January 2024
Accepted: 23 April 2024
First Online: 4 June 2024
Competing interests
: J.E.B. and M.W. are named as inventors on a patent (submitted by University College London Business Ltd (UCLB); no. WO2021255460), which covers developmental aspects of the WID-qCIN test. M.W., L.S. and E.R. are listed as inventors on a priority patent application (submitted by Sola Diagnostics GmbH; no. GB2401477.1) covering the optimization of the WID-qCIN test. J.E.B., C.H. and M.W. are shareholders in Sola Diagnostics GmbH, which holds exclusive licenses to the respective intellectual property rights that protect the commercialization of the WID-qCIN test. K.S. has received consulting fees and research grants from Merck Sharp and Dohme Corp. to her affiliating institution for studies on HPV vaccination in Sweden. The other authors declare no competing interests.
